Cancer News and Research

Latest Cancer News and Research

Class of cells that arises in mammary glands during maternity has stem cell-like properties

These parity-induced mammary epithelial cells (PI-MEC) have the ability to self-renew over many generations and to differentiate into numerous cellular subtypes.

7 Dec 2004

Gauging the risk from prolonged low-level radiation

Everyone knows that high doses of radiation are dangerous, but the effects of long-term exposure to low-level radiation is poorly understood. RISC-RAD, a new European Union backed research project, seeks to identify our tolerance threshold so as to optimise protective measures.

7 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

Electrochemical DNA chip that is able to detect DNA at very low concentrations

Toshiba Corporation has announced the development of a highly sensitive electrochemical DNA chip that is able to detect DNA at very low concentrations, a capability that will support advances in gene detection and analysis for individual treatment regimes, and the monitoring of healthy individuals for any predisposition to certain diseases.

6 Dec 2004

Smoking, a major problem in plastic surgery

Smoking is known to cause heart disease and cancer, but most patients do not know that smoking can harm the chances of having successful plastic surgery operations.

6 Dec 2004

Scientist develops way to deliver promising genetic tool into living cells

By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.

6 Dec 2004

Family history not age greatly affects breast cancer risk

CancerBACUP has published the results of a survey revealing that more over 50s believe that family history - not age - greatly affects breast cancer risk.

6 Dec 2004

First live imaging of specialized immune system cells reveals new clues about body’s security system

To keep the body safe, the immune system enlists more than one form of protection. A circulating task force of immune system cells monitors the body’s periphery, and sends information back to field command centers — the lymph nodes — located at pivotal traffic points.

6 Dec 2004

Two recent studies are souring milk's image among health authorities

Two recent studies are souring milk's image among health authorities. One, published in the November issue of the American Journal of Clinical Nutrition, shows that women who consume two or more glasses of milk a day have twice the risk of a certain form of ovarian cancer than those who rarely or never consume milk.

6 Dec 2004

Episome vectors offer fresh angle to gene therapy

A European research team is seeking to overcome the early setbacks suffered by the promising new field of ‘gene therapy’ by developing a revolutionary delivery technique, known as ‘episome vectors’. This breakthrough could pave the way to treating hereditary diseases by injecting the body with healthy versions of damaged genes.

6 Dec 2004

290,000 Australians have been exposed to UV radiation in the past year due to solarium use

Cancer Council Australia has released alarming statistics showing that over 290,000 Australians have been exposed to UV radiation in the past year due to solarium use.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004